Medical Condition News

RSS

Roche introduces new EMR interface for the U.S. Department of VA

Roche announced today that it has introduced a new Electronic Medical Record interface for the U.S. Department of Veterans Affairs that helps VA healthcare facilities improve their efficiency and accuracy by transmitting patient diabetes management data directly into the VistA computerized patient record system.

From Roche Sequencing and Life Science 19 Apr 2011

Japan Tobacco and Torii commence ferric citrate Phase 3 clinical program for hyperphosphatemia

Keryx Biopharmaceuticals, Inc., announced today that its Japanese partner, Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co., Ltd., JT's pharmaceutical business subsidiary, has commenced the Phase 3 clinical program of ferric citrate in Japan for the treatment of patients with hyperphosphatemia.

18 Apr 2011

Tweaking gene in satellite cells may increase lifespan of people with muscular dystrophy

Researchers have long questioned why patients with Duchenne muscular dystrophy (DMD) tend to manage well through childhood and adolescence, yet succumb to their disease in early adulthood, or why elderly people who lose muscle strength following bed rest find it difficult or impossible to regain.

18 Apr 2011

Non-alcoholic fatty liver disease linked to coronary artery disease

Because of the prevalence of obesity in our country, many Americans are expected to develop a serious condition called non-alcoholic fatty liver disease (NAFLD), which can lead to cirrhosis, fibrosis, and in some cases liver failure. It is also one of the best predictors for coronary artery disease.

18 Apr 2011

Novel lifestyle program may slow loss of brain cells due to aging and also grow new cells

In March, more than 80 residents at Emeritus at Ocoee, an assisted living and memory care community in Central Florida, began a new and highly promising research-based Brain Health Lifestyle Program which was designed to not only slow the loss of brain cells due to aging, but also grow new cells.

18 Apr 2011

St. Jude Medical's Accent MRI pacemaker and Tendril MRI lead system receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced that it has received European CE Mark approval for its Accent MRI™ pacemaker and Tendril MRI™ lead. The system, designed and tested for safe use in a Magnetic Resonance Imaging (MRI) environment and approved as MR-Conditional, allows patients to undergo full-body, high-resolution MRI scans.

18 Apr 2011

FDA accepts Regeneron's VEGF Trap-Eye BLA for review

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted for review the Company's Biologics License Application for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.

18 Apr 2011

Biotech Synergy concludes EP-2101 asset transfer, cancer epitopes related portfolio

Biotech Synergy has concluded the asset transfer of multi-epitope cancer vaccine product formerly known as EP-2101 and cancer epitopes related portfolio. Emile Loria, M.D., former President and Chief Business Officer of IDM and former President & CEO of Epimmune, is the founder of Biotech Synergy.

18 Apr 2011

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101.

18 Apr 2011

Ipsen, Active Biotech sign deal to co-develop and commercialize TASQ

Active Biotech AB and Ipsen announced today that they have entered into a broad partnership to co-develop and commercialize Active Biotech's investigational compound Tasquinimod "TASQ".

18 Apr 2011

Scientists develop new compound for multiple sclerosis treatment

Scientists from the Florida campus of The Scripps Research Institute have developed the first of a new class of highly selective compounds that effectively suppresses the severity of multiple sclerosis in animal models.

18 Apr 2011

Blue Cross launches 'The Human Do.ing' project to improve communities' health

He danced. He grooved. He walked. He sweated. And in the end, he did something he wasn't sure was possible. He got healthy. On Saturday, Twin Cities man Scott Jorgenson, 45, ended his 30 days as "The Human Do.ing," a project developed by Blue Cross and Blue Shield of Minnesota as part of the company's do. Campaign to "groove your body every day" to achieve better health.

18 Apr 2011

'The Invisible Gorilla' test for inattention blindness

University of Utah psychologists have learned why many people experience "inattention blindness" - the phenomenon that leaves drivers on cell phones prone to traffic accidents and makes a gorilla invisible to viewers of a famous video.

18 Apr 2011

Non-Hispanic black infants born with heart defects more likely to die within five years

Non-Hispanic black infants born with heart defects are more likely to die within the first five years of life than their non-Hispanic white and Hispanic peers. For certain types of congenital heart abnormalities, Hispanic children as well as non-Hispanic black children fare worse than non-Hispanic white children.

18 Apr 2011

New guidelines for cardiac specialists

A series of new guidelines for cardiac specialists has been developed to determine when heart failure patients should receive a mechanical heart-pumping device.

18 Apr 2011

Eye physicians need to include low-cost molecular medicine in their tool box

Dr. Richer, speaking at his 4th annual Nutrition & The Eye conference, April 16-17, hosted by the College of Optometry at the University of Missouri in St. Louis, says molecular medicine is beginning to provide hope for patients with declining sight when all other therapies have been exhausted.

18 Apr 2011

Researchers discover strategy that promotes new blood vessel formation

Researchers at The University of Western Ontario have discovered a strategy for stimulating the formation of highly functional new blood vessels in tissues that are starved of oxygen. Dr. Geoffrey Pickering and Matthew Frontini at the Schulich School of Medicine & Dentistry developed a strategy in which a biological factor, called fibroblast growth factor 9, is delivered at the same time that the body is making its own effort at forming new blood vessels in vulnerable or damaged tissue.

18 Apr 2011

Scientist discovers new molecular mechanism underlying asthma, COPD

Michael Croft, Ph.D., a researcher at the La Jolla Institute for Allergy & Immunology, has discovered a molecule's previously unknown role as a major trigger for airway remodeling, which impairs lung function, making the molecule a promising therapeutic target for chronic asthma, chronic obstructive pulmonary disease and several other lung conditions.

18 Apr 2011

Patients with schizophrenia can benefit from L-lysine treatment

Schizophrenia is a serious mental disorder that currently affects about one in every 200 people. Most patients find some relief from their symptoms by treatment with antipsychotics, however they may still suffer from cognitive and negative symptoms.

18 Apr 2011

Sarcasm and lie detection failure signals dementia: Study

Researchers have found that inability to recognize others' insincerity, lies and sarcasm could be a warning sign of a form of dementia. They found that people with frontotemporal dementia - a type of dementia that affects the frontal and temporal lobes of the brain - often lose the ability to detect sarcasm and lies, while people who grow older normally don't experience this.

17 Apr 2011